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Poster Session-I 45demonstrated CBMC can be ex-vivo expanded by K562 cells ex-
pressing membrane bound IL15 and 4-1BB ligand (K562-mbIL15-
41BBL) resulting in specific expansion of CB NK cells and decrease
in CB T-Cells.113
A ‘‘NO-WASH’’ ALBUMIN-DEXTRAN DILUTION STRATEGY FOR CORD
BLOOD (CB) THAW IS ASSOCIATED WITH A HIGH RATE OF ENGRAFT-
MENT AND A LOW INCIDENCE OF SERIOUS INFUSION REACTIONS
Rice, R.D., Abboud, M., Hawke, R.M., Schaible, A.M., Heller, G.,
Scaradavou, A., Barker, J.N. Memorial Sloan-Kettering Cancer Center,
New York, NY
The albumin-dextran dilutionwith centrifugation (‘‘wash’’) for CB
thaw used for children has been adopted for adults as a matter of con-
vention. An alternative CB dilution without centrifugation may be
advantageous for adults in whom any cell loss may be significant.
In contrast to a bedside thaw, it is still conducted in the controlled
laboratory environment. Therefore, we conducted a prospective
study of CB transplantation (CBT) using albumin-dextran dilution
with the hypothesis that the ‘‘no wash’’ thaw would be associated
with tolerable infusion reactions and a high rate of engraftment. Re-
cipients $20 kg were eligible. Patients [n 5 50; median 42 years
(range 7–66); median 72 kg (range 24–109)] were transplanted for
high-risk hematological malignancies with ablative (n 5 34) or
non-ablative (n 5 16) conditioning and double unit grafts to aug-
ment engraftment. 99 units were thawed with albumin-dextran dilu-
tion (1 RBC replete unit was washed). Units were 6/6 (n5 5), 5/6 (n
5 52) and 4/6 (n 5 42) HLA-A,B antigen, DRB1 allele matched to
the recipient. A 5:1 Gentran40/ 25% albumin solution was used.
RBC deplete units (n 5 96) were diluted $5.5 fold [median
200mls (range 200–500)]. The larger volume RBC replete units (n
5 3) were diluted $4 fold [median 400mls (range 400–535)] using
double tubing to connect to the transfer pack to prevent clogging.
All patients received pre-medication and pre- and post-hydration.
There were no serious adverse events related to infusion. 18 had
no reactions and 32 had reactions requiring additional therapy (2
transient hypoxia, 29 hypertension, 6 nausea, 3 pain, 1 rigor/fever).
Also, 1 had transient bradycardia and 6 had transient creatinine ele-
vation. Cumulative incidence (CI) of sustained donor engraftment
was 96% (95%CI:90–100) with neutrophil recovery at a median of
25 days (range 13–43) in ablative and 11 days (range 7–36) in non-
ablative recipients. CI of day 100 grade II-IV acute GVHD was
40% (95%CI:26–54), and 6 patients have chronic GVHD to date.
CI of day 180 transplant-related mortality is 24% (95%CI:11–37)
and 1 year overall survival is 63%(95%CI:49–78). In conclusion,
the dilution thaw technique is an alternative to wash in patients
$20 kg with cell dose yields and clinical outcomes that compare
favorably to a traditional wash. This technique is more efficient,
reduces unit manipulation, speeds time to infusion, reduces cell
loss, and may be the thaw technique of choice for adult CBT.
Post-Thaw Cell Dose Yields
Pre-thaw Post-thaw Post-thaw Post-thaw
TNC x
107/kgTNC x
107/kg% TNC
RecoveryCD341
ViabilityCD341 x
105/kg/unitCFU-GM x
104/kg/unitMedian 2.65 2.25 86% 90% 0.90 1.25
Range 1.06–6.87 0.92–5.36 50–121% 34–98% 0.13–3.69 0.00–4.38114
COLONY-FORMING-UNIT (CFU) ASSAY WITH HIGH-RESOLUTION
DIGITAL IMAGING: A RELIABLE SYSTEM FOR CORD BLOOD (CB) CFU
EVALUATION
Albano, M.S., Stevens, C.E., Dobrila, L.N., Scaradavou, A.,
Rubinstein, P. New York Blood Center, New York, NY
Among CB graft characteristics currently used as determinants of
quality and engraftment potential, only the CFU assay evaluates the
functional state and number of hematopoietic progenitor cells. Tra-
ditionally, classification and enumeration of CFU colonies are per-
formed manually by light microscopy, and the assay is timeconsuming, subjective and difficult to standardize. We developed
a strategy combining high resolution digital imaging and colony
staining with MTT, which allows testing of large numbers of CB
samples in a ‘‘high throughput’’ approach. CFU growth was assessed
in 2159 CB units; samples were obtained after processing (AXP
system). Our new approach permits a more precise analysis, classifi-
cation, and enumeration of the different colonies, and standardiza-
tion of the assay. Furthermore, stored CFU images can be
reviewed prior to the release of a CBU for transplantation. The num-
ber of CFUs (179 6108/uL) correlated strongly with Total Nucle-
ated Cell count (R2: 0.33), Mononuclear Cell count (MNC
1nucleated RBC, R2: 0.35), and especially with pre-processing
CD341 cell content (R2: 0.8, all p\0.001). Comparison with results
obtained by the traditional CFU assay when testing was performed
on pre-processing samples showed minimal difference (10–15%) in
the CFU/uL or CFU/MNC ratio. CFU evaluation from a frozen-
thawed segment attached to the CBU bag is now underway. Even
though a small number of segments were tested so far (n 5 15),
CFU/uL correlated with the CBU’s respective pre-freeze CD341
cells (R2: 0.78), and with the post-thaw CD341 cells from the
same segment (R2: 0.74). CD341 cell viability was.93% in all seg-
ments. In summary, CFUs can be enumerated reliably fromCB sam-
ples with a new strategy that can be standardized. The feasibility of
CFU growth from thawed segments was also evaluated, and CFU
yield correlated strongly with post-processing and segment-derived
CD341 cell counts. This assay can be used as a practical quality con-
trol measure of the cryopreservation process prior to a CBU release
for transplantation. Studies are in progress to assess whether CFU
yield from a segment could predict engraftment and, therefore,
used for the selection of CB units for transplantation.115
REGULATORY T CELL S (Tregs) CAN BE ISOLATED FROM G-CSF MOBI-
LIZED PBSC AFTER MONOCYTE DEPLETION AND INHIBIT ANTI-STEM
CELL T CELL ALLOREACTIVITY
Mahmud, D., Rondelli, D. University of Illinois at Chicago, Chicago, IL
Small numbers of human CD41CD251FoxP31 Tregs can be
isolated from normal peripheral blood, thus their potential clinical ap-
plication is limited. In this study we tested whether Granulocyte Col-
ony-Stimulating Factor (G-CSF)-mobilized peripheral blood stem
cells (PBSC) from healthy donors can represent a useful source of
CD41CD251 cells with regulatory activity. We utilized antibodies
conjugated tomicrobeads (Miltenyi Biotec Inc,Auburn,CA) to immu-
nomagnetically separate the cells on a MidiMACS device (Miltenyi)
and checked the purity after isolation by flow cytometry. Starting
from on average 4.0 6 1.8  108 unseparated PBSC (n 5 3) we
positively selected 2.46 0.8  106 CD341 cells (.90% purity). We
then utilized the CD34- cell fraction to isolateTregs. Due to the large
content of CD4dim monocytes in the initial cell product, we initially
depleted the PBSC of CD141 cells and then utilized a two-step pro-
cess that includes a CD41 cell negative selection (using a cocktail of
biotin-conjugated antibodies against CD8, CD14, CD19, CD16,
CD36, CD56, CD123, TCR g/d and Glycophorin-A) followed by
a positive selection of CD251 cells (Treg isolation kit, Miltenyi).
This process allowed us to obtain 1.26 1  106 CD41CD251 cells
with a purity of.70%. Intracellular expression of FoxP3 was also de-
tected in purified CD41CD251 cells by flow cytometry. Primary
mixed leukocyte cultures (MLC) were performed with irradiated
CD341 cells isolated from PBSC and HLA mismatched blood
CD31 responders for 6 days and T cell response was measured by
a 3H-thymidine uptake assay. Tregs isolated from PBSC were added
to the MLC at 1:2 Treg:responder ratio to test their regulatory func-
tion. Control experiments were performed using CD41CD25- cells.
AdditionofTregs isolated fromPBSCresulted in 766 17%inhibition
of anti-CD34T cell alloreactivity (cpm: 190006 530 vs 45906 1880)
(n5 3), while control CD41CD25 neg cells did not show suppressive
activity. These findings show that after isolation of CD341 cells, ade-
quate numbers of Tregs can be obtained from the CD34- cell fraction
ofPBSCbyusinga three-stepprocess. In addition, sinceTregs isolated
from PBSC suppressed in-vitro T cell alloreactivity against CD341
cells, these findings will prompt the design of pre-clinical studies to
test the combination of PBSC-derived CD341 cells and Tregs in
HLA mismatched transplantation.
